-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Disc Medicine, Lowers Price Target to $88

Benzinga·02/17/2026 14:33:12
Listen to the news
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and lowers the price target from $110 to $88.